Company intelligence / Profile preview

ImCare Biotech

Doylestown, Pennsylvania, United Statesimcarebiotech.com ↗

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

ImCare Biotech has developed Seravue®, a diagnostic test for Hepatocellular Carcinoma (HCC) that received FDA Breakthrough Device designation in June 2020. The company completed a prospective, blinded clinical study with over 500 patients to evaluate the use of their novel biomarker for detecting HCC in early and later stages[7].

Therapeutic areas: GastroenterologyOncology
Modalities: Diagnostic immunoassaysMonoclonal antibodies
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

Seravue

Commercial

Indications: Hepatocellular carcinoma

Partnerships

National Cancer Institute (NCI/NIH)

Beyond the preview

Go deeper on ImCare Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImCare Biotech.

Explore the full profile